BRAF, a serine/threonine kinase and central effector of the MAPK/ERK pathway, though rarely mutated in serous ovarian carcinoma (SOC), may contribute to tumor progression through non-mutational overexpression [31]. This evidence concerns the gene MARK2 and neoplasm.